Emerald Advisers, LLC Amylyx Pharmaceuticals, Inc. Transaction History

Emerald Advisers, LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 05, 2024	SELL	$12.07 - $18.46 $434,061 - $663,858	-35,962 Reduced 4.29%	802,610 $11.8 Million
Q3 2023 Oct 26, 2023	BUY	$18.08 - $23.45 $122,293 - $158,615	6,764 Added 0.81%	838,572 $15.4 Million
Q2 2023 Jul 25, 2023	SELL	$20.98 - $31.42 $2.96 Million - $4.43 Million	-141,027 Reduced 14.5%	831,808 $17.9 Million
Q1 2023 May 04, 2023	BUY	$27.71 - $40.93 $3.77 Million - $5.56 Million	135,926 Added 16.24%	972,835 $28.5 Million
Q4 2022 Feb 03, 2023	BUY	$29.75 - $39.26 $7.01 Million - $9.25 Million	235,683 Added 39.2%	836,909 $30.9 Million
Q3 2022 Oct 25, 2022	BUY	$17.15 - $30.92 $10.3 Million - $18.6 Million	601,226 New	601,226 $16.9 Million

127

44.4M

235K

530K

Ticker AMLX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 58,533,200
Market Cap $308M
Description
Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment...

Get notified when there are updates to the investment portfolio of Emerald Advisers, LLC, based on Form 13F filings with the SEC.

Stay updated on Emerald Advisers, LLC with notifications on news.